Strategic partnerships Leverage the recent Zydus Lifesciences collaboration and ongoing MSK-ACCESS joint development to position Myriad Genetics as a leader in global diagnostic collaborations. Explore co-development, licensing, or distribution deals targeting multinational pharma and CROs seeking companion diagnostics.

Expanded MRD opportunities Capitalizing on newly launched Precise MRD and breast cancer MRD tests, pursue outreach to oncology clinics, surgical centers, and value-based care networks prioritizing minimal residual disease monitoring to improve treatment decisions and patient outcomes.

AI enabled solutions Promote Prolaris + AI and other AI-assisted assays to payors and hospital systems aiming to enhance risk stratification, reduce unnecessary treatments, and lower costs. Highlight data science capabilities and outcomes from AI-enabled tests.

Leadership & digitization With leadership changes including a new CTO and emphasis on digital infrastructure, target technology-forward health systems and diagnostics integrators for seamless ELT (extract, load, transform) data pipelines, APIs, and interoperability with PostgreSQL and JSON-LD based data models.

Global expansion Capitalize on the global focus of the liquid biopsy companion diagnostic program and ongoing partnerships to target international markets, regional distributors, and healthcare networks seeking scalable, ctDNA-based tests aligned with precision medicine strategies.